Pfizer and Allergan merger talks at early stage

Pharmaceutical company Pfizer has confirmed it has entered into talks with generics company Allergan over a potential merger.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

Americas

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

More features

All eyes on Squires: What IP experts want from the new USPTO director

Crafting claim strategies in animal and human therapeutics

MSD scores second win in patent fight over Keytruda

Scientist jumps from Jones Day to expand rival’s biotech offering

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

Pfizer and Allergan merger talks at early stage

More on this story

Editor's picks

Editor's picks

More features